Compare Amphastar Pharmaceuticals Inc (AMPH) vs ZIM Integrated Shipping Services Ltd (ZIM) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

ZIM trades at $23.97, down 0.7% on the day, with a bearish technical signal from moving averages. The company reported a Q1 2026 net loss of $86 million, missing EPS expectations, though revenue pressure from lower freight rates may be offset by recent supply chain disruptions. Valuation metrics show a low P/S of 0.46 and P/B of 0.76, suggesting potential undervaluation relative to assets. Key developments include a pending merger with Hapag-Lloyd facing regulatory hurdles and a rival $4.5 billion takeover bid from Haim Sakal.

The outlook for ZIM is clouded by operational challenges and merger uncertainty, but current asset-based valuations provide a floor near $29–$30 per share. Investment opportunity exists if merger approvals proceed or freight rates rebound from Hormuz blockade effects. Primary risks include regulatory rejection of deals, sustained earnings pressure, and high debt-to-asset ratio of 0.71. Analyst consensus is split evenly between Hold and Sell with a $16.75 price target, indicating cautious sentiment amid speculative M&A dynamics.